Mapi Pharma swings for $50M haul as oft-delayed IPO nears D-Day

Nick Paul Taylor

has set the terms for its latest crack at listing on Nasdaq. The biotech, which set terms on its first IPO attempt back in April 2014, is aiming to round up around $ 50 million (€46 million) to bankroll development of its once-a-month version of Teva's blockbuster Copaxone.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS